These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 28392127)

  • 21. Analysis of cancer/testis antigens in sporadic medullary thyroid carcinoma: expression and humoral response to NY-ESO-1.
    Maio M; Coral S; Sigalotti L; Elisei R; Romei C; Rossi G; Cortini E; Colizzi F; Fenzi G; Altomonte M; Pinchera A; Vitale M
    J Clin Endocrinol Metab; 2003 Feb; 88(2):748-54. PubMed ID: 12574209
    [TBL] [Abstract][Full Text] [Related]  

  • 22. NY-ESO-1 protein expression in primary breast carcinoma and metastases: correlation with CD8+ T-cell and CD79a+ plasmacytic/B-cell infiltration.
    Theurillat JP; Ingold F; Frei C; Zippelius A; Varga Z; Seifert B; Chen YT; Jäger D; Knuth A; Moch H
    Int J Cancer; 2007 Jun; 120(11):2411-7. PubMed ID: 17294444
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fine-mapping naturally occurring NY-ESO-1 antibody epitopes in melanoma patients' sera using short overlapping peptides and full-length recombinant protein.
    Komatsu N; Jackson HM; Chan KF; Oveissi S; Cebon J; Itoh K; Chen W
    Mol Immunol; 2013 Jul; 54(3-4):465-71. PubMed ID: 23454162
    [TBL] [Abstract][Full Text] [Related]  

  • 24. First-in-Class, First-in-Human Study Evaluating LV305, a Dendritic-Cell Tropic Lentiviral Vector, in Sarcoma and Other Solid Tumors Expressing NY-ESO-1.
    Somaiah N; Block MS; Kim JW; Shapiro GI; Do KT; Hwu P; Eder JP; Jones RL; Lu H; Ter Meulen JH; Bohac C; Chen M; Hsu FJ; Gnjatic S; Pollack SM
    Clin Cancer Res; 2019 Oct; 25(19):5808-5817. PubMed ID: 31227504
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Increased NY-ESO-1 expression and reduced infiltrating CD3+ T cells in cutaneous melanoma.
    Giavina-Bianchi M; Giavina-Bianchi P; Sotto MN; Muzikansky A; Kalil J; Festa-Neto C; Duncan LM
    J Immunol Res; 2015; 2015():761378. PubMed ID: 25954764
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients.
    Odunsi K; Matsuzaki J; Karbach J; Neumann A; Mhawech-Fauceglia P; Miller A; Beck A; Morrison CD; Ritter G; Godoy H; Lele S; duPont N; Edwards R; Shrikant P; Old LJ; Gnjatic S; Jäger E
    Proc Natl Acad Sci U S A; 2012 Apr; 109(15):5797-802. PubMed ID: 22454499
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predictive and prognostic effect of CD133 and cancer-testis antigens in stage Ib-IIIA non-small cell lung cancer.
    Su C; Xu Y; Li X; Ren S; Zhao C; Hou L; Ye Z; Zhou C
    Int J Clin Exp Pathol; 2015; 8(5):5509-18. PubMed ID: 26191258
    [TBL] [Abstract][Full Text] [Related]  

  • 28. LUD 00-009: phase 1 study of intensive course immunization with NY-ESO-1 peptides in HLA-A2 positive patients with NY-ESO-1-expressing cancer.
    Bender A; Karbach J; Neumann A; Jäger D; Al-Batran SE; Atmaca A; Weidmann E; Biskamp M; Gnjatic S; Pan L; Hoffman E; Old LJ; Knuth A; Jäger E
    Cancer Immun; 2007 Oct; 7():16. PubMed ID: 17944437
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of LAGE-1 and NY-ESO-1 expression in multiple myeloma patients to explore possible benefits of their homology for immunotherapy.
    de Carvalho F; Vettore AL; Inaoka RJ; Karia B; Andrade VC; Gnjatic S; Jungbluth AA; Colleoni GW
    Cancer Immun; 2011 Jan; 11():1. PubMed ID: 21247062
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression profile of cancer-testis genes in 121 human colorectal cancer tissue and adjacent normal tissue.
    Li M; Yuan YH; Han Y; Liu YX; Yan L; Wang Y; Gu J
    Clin Cancer Res; 2005 Mar; 11(5):1809-14. PubMed ID: 15756003
    [TBL] [Abstract][Full Text] [Related]  

  • 31. NY-ESO-1 antigen: A promising frontier in cancer immunotherapy.
    Alsalloum A; Shevchenko JA; Sennikov S
    Clin Transl Med; 2024 Sep; 14(9):e70020. PubMed ID: 39275923
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumor-reactive CD8+ T-cell responses after vaccination with NY-ESO-1 peptide, CpG 7909 and Montanide ISA-51: association with survival.
    Karbach J; Gnjatic S; Bender A; Neumann A; Weidmann E; Yuan J; Ferrara CA; Hoffmann E; Old LJ; Altorki NK; Jäger E
    Int J Cancer; 2010 Feb; 126(4):909-18. PubMed ID: 19728336
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Heteroclitic serological response in esophageal and prostate cancer patients after NY-ESO-1 protein vaccination.
    Kawada J; Wada H; Isobe M; Gnjatic S; Nishikawa H; Jungbluth AA; Okazaki N; Uenaka A; Nakamura Y; Fujiwara S; Mizuno N; Saika T; Ritter E; Yamasaki M; Miyata H; Ritter G; Murphy R; Venhaus R; Pan L; Old LJ; Doki Y; Nakayama E
    Int J Cancer; 2012 Feb; 130(3):584-92. PubMed ID: 21413013
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparisons for detecting NY-ESO-1 mRNA expression levels in hepatocellular carcinoma tissues.
    Wang XY; Chen HS; Luo S; Zhang HH; Fei R; Cai J
    Oncol Rep; 2009 Mar; 21(3):713-9. PubMed ID: 19212631
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HLA superfamily assignment is a predictor of immune response to cancer testis antigens and survival in ovarian cancer.
    Szender JB; Eng KH; Matsuzaki J; Miliotto A; Gnjatic S; Tsuji T; Odunsi K
    Gynecol Oncol; 2016 Jul; 142(1):158-162. PubMed ID: 27103177
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intertumor and intratumor NY-ESO-1 expression heterogeneity is associated with promoter-specific and global DNA methylation status in ovarian cancer.
    Woloszynska-Read A; Mhawech-Fauceglia P; Yu J; Odunsi K; Karpf AR
    Clin Cancer Res; 2008 Jun; 14(11):3283-90. PubMed ID: 18519754
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analysis of peripheral and local anti-tumor immune response in esophageal cancer patients after NY-ESO-1 protein vaccination.
    Wada H; Sato E; Uenaka A; Isobe M; Kawabata R; Nakamura Y; Iwae S; Yonezawa K; Yamasaki M; Miyata H; Doki Y; Shiku H; Jungbluth AA; Ritter G; Murphy R; Hoffman EW; Old LJ; Monden M; Nakayama E
    Int J Cancer; 2008 Nov; 123(10):2362-9. PubMed ID: 18729190
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase II trial of ipilimumab in melanoma patients with preexisting humoural immune response to NY-ESO-1.
    Haag GM; Zoernig I; Hassel JC; Halama N; Dick J; Lang N; Podola L; Funk J; Ziegelmeier C; Juenger S; Bucur M; Umansky L; Falk CS; Freitag A; Karapanagiotou-Schenkel I; Beckhove P; Enk A; Jaeger D
    Eur J Cancer; 2018 Feb; 90():122-129. PubMed ID: 29306769
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MAGEA4 expression in bone and soft tissue tumors: its utility as a target for immunotherapy and diagnostic marker combined with NY-ESO-1.
    Iura K; Kohashi K; Ishii T; Maekawa A; Bekki H; Otsuka H; Yamada Y; Yamamoto H; Matsumoto Y; Iwamoto Y; Oda Y
    Virchows Arch; 2017 Sep; 471(3):383-392. PubMed ID: 28744588
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Simultaneous cytoplasmic and nuclear protein expression of melanoma antigen-A family and NY-ESO-1 cancer-testis antigens represents an independent marker for poor survival in head and neck cancer.
    Laban S; Atanackovic D; Luetkens T; Knecht R; Busch CJ; Freytag M; Spagnoli G; Ritter G; Hoffmann TK; Knuth A; Sauter G; Wilczak W; Blessmann M; Borgmann K; Muenscher A; Clauditz TS
    Int J Cancer; 2014 Sep; 135(5):1142-52. PubMed ID: 24482145
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.